Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Retaane® in Age-Related Macular Degeneration

This study has been completed.
Information provided by:
Rudolf Foundation Clinic Identifier:
First received: December 5, 2007
Last updated: December 6, 2007
Last verified: December 2007

The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.

While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.

Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.

Condition Intervention Phase
Age Related Macular Degeneration
Drug: juxtascleral depot injection of Retaane
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Retaane® in Age-Related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Rudolf Foundation Clinic:

Primary Outcome Measures:
  • Increase in VA [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Decrease in Macula Edema [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: February 2006
Study Completion Date: March 2007
Arms Assigned Interventions
Experimental: 1
Patients treated with Retaane
Drug: juxtascleral depot injection of Retaane
juxtascleral depot injection of Retaane


Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • rejection of intravitreal injections
  • presence of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration

Exclusion Criteria:

  • conditions precluding judgement of the fundus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00569569

Sponsors and Collaborators
Rudolf Foundation Clinic
Study Chair: Susanne Binder, M.D. no affiliation
  More Information

No publications provided Identifier: NCT00569569     History of Changes
Other Study ID Numbers: RFC012007
Study First Received: December 5, 2007
Last Updated: December 6, 2007
Health Authority: Austria: Ethikkommission

Additional relevant MeSH terms:
Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases processed this record on February 25, 2015